BPC-157 and the brain-gut axis: what the research describes
A plain-English read on a peptide first found in stomach juice and what the rodent research actually shows.
TL;DR
- BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice.
- Rodent research describes effects on the gastrointestinal lining, vagal nerve signaling, and dopamine/serotonin pathways.
- FDA removed BPC-157 from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.
What it is
BPC-157 (in plain English: body protection compound 157, a 15-amino-acid synthetic peptide based on a sequence isolated from human gastric juice) was first described by researchers at the University of Zagreb in the 1990s (Sikiric et al., Curr Pharm Des, 2018). The brain-gut axis (in plain English: the two-way communication system between your gastrointestinal tract and your brain, mostly running through the vagus nerve and circulating signals) has become a frequent subject of BPC-157 papers because the peptide originated in the gut.
How it works
Picture the gut and brain as two cities connected by a single highway — the vagus nerve. Think of BPC-157 in rodent studies as a peptide that helps repair the highway shoulder when traffic damages it. Published animal work describes BPC-157 protecting and rebuilding the stomach and intestinal lining after injury, supporting new blood vessel formation in damaged tissue, and modulating dopamine and serotonin signaling in pathways that connect gut and brain (Sikiric et al., 2018; Vukojevic et al., Front Neurosci, 2019).
Who asks about it
People come to this topic after a podcast or Reddit thread describes BPC-157 as a "gut healer." They want to know if the science backs the headline. The honest answer is that the rodent literature is large, the mechanism work is consistent, and human clinical trials are still limited. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
What the research says
A 2018 review in Current Pharmaceutical Design summarized roughly two decades of preclinical work on BPC-157 across gastrointestinal injury, ulcer healing, inflammatory bowel models, and brain-gut signaling (Sikiric et al., 2018). A 2019 paper in Frontiers in Neuroscience extended the picture into central nervous system models, describing dopamine system effects in rodents (Vukojevic et al., 2019). Human randomized clinical trials remain scarce.
What to know before considering it
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. The published evidence is overwhelmingly preclinical — that is animal and cell studies, not human clinical trials.
The Halftime POV
BPC-157 is one of the most-discussed peptides because the rodent data is striking. We are honest about what that data is and what it is not. Animal research is a starting hypothesis, not a human outcome. The right way to evaluate this peptide is to follow the regulatory path and the human trial pipeline — not the supplement aisle.
Related reading:
- BPC-157: what this body protection compound is
- How BPC-157 promotes tissue repair: the mechanism
- BPC-157: 30 years of animal research, what it tells us
FAQ
Q: What is BPC-157? A: BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. It has been studied for tissue repair effects in rodent models for roughly 30 years.
Q: What does BPC-157 do at the brain-gut axis in research? A: Rodent studies describe BPC-157 protecting and repairing the gastrointestinal lining, modulating dopamine and serotonin signaling, and influencing vagal nerve communication between gut and brain. Human clinical evidence is limited.
Q: Is BPC-157 available from compounding pharmacies in 2026? A: Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Sikiric P et al., Current Pharmaceutical Design, 2018 — BPC-157 in cytoprotection and the brain-gut axis
- Vukojevic J et al., Frontiers in Neuroscience, 2019 — BPC-157 and central dopamine signaling
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. It has been studied for tissue repair effects in rodent models for roughly 30 years.
What does BPC-157 do at the brain-gut axis in research?
Rodent studies describe BPC-157 protecting and repairing the gastrointestinal lining, modulating dopamine and serotonin signaling, and influencing vagal nerve communication between gut and brain. Human clinical evidence is limited.
Is BPC-157 available from compounding pharmacies in 2026?
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.